Figure 3: Cangrelor Reduces Human Platelet Thrombus Formation in Avatar Mice

<b>(A to D)</b> Time course of fluorescent platelets accumulating on laser-injured arterioles contained with the cremaster muscle of von Willebrand factor^HA1 mice. Cangrelor (30-μg/kg bolus; 4-μg/kg/min infusion) or abciximab (0.25-μg/kg bolus; 0.125-μg/kg/min infusion) were administered intravenously after establishing baseline thrombus formation in the absence of drug. n = 15 (age 0 to 28 days); n = 10 (age 1 to 10 years); n = 8 (age 11 to 18 years); n = 15 for adults. <b>(E)</b> Maximal thrombus size pre- and post-administration of cangrelor in the same animal. Each symbol represents the area of a thrombus in 1 arteriole of an avatar mouse. <b>(F)</b> Percent change in thrombus size in response to cangrelor treatment based on data shown in <b>E</b>. See Supplemental Video 2. Data represent mean ± SEM. ***p &lt; 0.001 for drug versus no treatment according to the Mann-Whitney <i>U</i> test.

**(A至D)** 携带HA1型血管性血友病因子（von Willebrand factor）的小鼠提睾肌内，激光损伤小动脉表面荧光血小板聚集的动态变化过程。在未施加药物的情况下建立基线血栓形成模型后，经静脉给予坎格雷洛（30μg/kg推注；4μg/kg/min持续输注）或阿昔单抗（0.25μg/kg推注；0.125μg/kg/min持续输注）。样本量分别为：0~28日龄小鼠15只，1~10岁龄小鼠10只，11~18岁龄小鼠8只，成年小鼠15只。
**(E)** 同一只小鼠在给予坎格雷洛前后的最大血栓尺寸。每个数据点代表单只受试小鼠单条小动脉内的血栓面积。
**(F)** 基于图**E**所示数据，坎格雷洛治疗后血栓尺寸的变化百分比。详见补充视频2。数据以平均值±标准误（standard error of the mean, SEM）表示。根据曼-惠特尼U检验（Mann-Whitney U test），给药组与未给药组相比，***p < 0.001。